Insulin Initiation and Adherence Behaviours: a Cross Sectional Survey of Indian HCPs & Patients With Type 2 Diabetes

NCT06517784 | Completed

• 2 other identifiers: NN000-7941U1111-1302-7518
• Study Type: observational
• Target: 752
• Locations: 1 country
• Sites: 1

Brief Summary

This is a cross-sectional study planned among patients with Type 2 Diabetes (T2D) and Health Care Providers (HCPs) who treat T2D patients. Study participants will be recruited through existing databases/panels to complete a 30-minute self-administered online survey. The purpose of the study is to understand the insulinization barriers and the insulin adherence behaviours of both HCPs and patients.

Conditions

Type 2 Diabetes

Outcome Measures

Primary Outcomes (1)

• The barriers toward insulin initiation among HCPs & patients

  Barriers to insulin initiation = Likert scale: 1=Strongly disagree, 5=Strongly agree

  At time of data abstraction (Day 1)

Study Arms (2)

Patients

Patients with type 2 diabetes

Other: No treatment given

Health care providers

Health care providers who treat patients with type 2 diabetes

Other: No treatment given

Interventions

No treatment given OTHER

No treatment given

Health care providers; Patients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with Type 2 Diabetes (T2D) and Health Care Providers (HCPs) who treat T2D patients

You may qualify if:

• For patients
• Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
• Male or female, age above or equal to 18 years at the time of signing informed consent.
• Diagnosed with T2D
• Currently seeing an HCP for T2D
• Initiated on insulin within the past 12 months
• Prescribed insulin on a permanent basis
• Currently taking insulin via a vial and syringe or insulin pen
• For HCP
• Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
• Male or female, age above or equal to 18 years at the time of signing informed consent.
• Primary care physician (PCP) with degree in internal medicine or general medicine, diabetologist with degree in internal medicine or general medicine plus diploma in diabetology, or endocrinologist
• Has been in practice a minimum of 2 years
• Diabetologist/endocrinologist: treats at least 50 T2D patients per month
• PCP: treats at least 40 T2D patients per month

You may not qualify if:

• Previous participation in this study. Participation is defined as having given informed consent in this study
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (1)

Novo Nordisk India

Bangalore, India

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Officials

• Clinical Transparency dept. 2834

  Novo Nordisk A/S

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 18, 2024
• First Posted: July 24, 2024
• Study Start: July 5, 2024
• Primary Completion: August 16, 2024
• Study Completion: August 16, 2024
• Last Updated: August 28, 2024

Record last verified: 2024-08

Data Sharing

• IPD Sharing: Will share

Locations

IN (1)